Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

--Vigil Neuroscience, Inc., a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi, today announced that ...

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the ...

Net Loss: Net loss from operations for the first quarter ended March 31, 2025 were $22.4 million, compared to $19.9 million for the same period in 2024. About Vigil Neuroscience ...

Vigil Neuroscience, Inc. (VIGL) closed the last trading session at $7.88, gaining 225.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi. French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing ...

Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 mi ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following ...

--Vigil Neuroscience, Inc., a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the ...